Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02134015 · ClinicalTrials.gov registry record · Phase 3
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
A Phase 3 study, sponsored by Daiichi Sankyo.
- Terminated
- Registry status
- Phase 3
- Development phase
- 145
- Enrollment target
NCT02134015 is a Phase 3 study that was terminated before completion, run by Daiichi Sankyo. The registered enrollment target is 145 participants.
The verdict
NCT02134015, a Phase 3 study, was terminated before completion, sponsored by Daiichi Sankyo.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 145 participants
- Enrollment target
Study Summary
1. Part A: Subjects will receive Patritumab or placebo with erlotinib. Progression-free survival will be the primary outcome. Subjects will need to have Epidermal Growth Factor Receptor (EGFR) wild-type, locally advance or metastatic NSCLC and have their cancer progressed after at least one prior systemic anti-cancer therapy, available recent or archival tumor specimen and may not have had previous EGFR-targeted regimen, anti-HER2 (Human Epidermal Growth Factor Receptor 2), anti-HER3, or anti-HER4 therapy. Subjects may have high heregulin or low heregulin. 2. Part B: Subjects will receive Patritumab or placebo with erlotinib. Overall survival will be the primary outcome. Subjects will need to have EGFR wild-type, locally advance or metastatic NSCLC and have their cancer progressed after at least one prior systemic anti-cancer therapy, available recent or archival tumor specimen and may not have had previous EGFR-targeted regimen, anti-HER2, anti-HER3, or anti-HER4 therapy. Only subjects with high heregulin will be enrolled.
Interventions
- DRUG Placebo
- DRUG Erlotinib
- DRUG Patritumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-11-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02134015
The ClinicalTrials.gov registry entry for NCT02134015 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02134015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02134015 about?
NCT02134015 is a clinical study titled "Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)". 1. Part A: Subjects will receive Patritumab or placebo with erlotinib. Progression-free survival will be the primary outcome. Subjects will need to have Epidermal Growth Factor Receptor (EGFR) wild-type, locally advance or metastatic NSCLC and have their cancer progressed after at least one prior sy...
What is the current status of trial NCT02134015?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 145 participants. The study started on 2014-03. Estimated completion is 2016-11-11.
What interventions are being tested in trial NCT02134015?
The interventions under investigation include: Placebo (DRUG), Erlotinib (DRUG), Patritumab (DRUG).
Who is sponsoring clinical trial NCT02134015?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.